Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Personalized Drug Response: IMplementation and Evaluation in CKD (PRIME-CKD)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Unlocking the full potential of new tools, technologies and digital solutions for a healthy society
Action type: Research and Innovation actions
Countries involved: Netherlands,United States,Sweden,Denmark,Ireland,Germany,Italy,United Kingdom,Spain
Call: Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers (HORIZON-HLTH-2022-TOOL-11, 2022)
Start date: 2023-01-01
End date: 2027-12-31
Duration (months): 60.0
Total project cost (EUR): 9242241.01
EU funding (EUR): 9242240.51
Participants: 17
Project status: SIGNED

Chronic Kidney Disease (CKD) is one of the major causes of death in high income countries and its prevalence is growing rapidly. New therapies for the treatment of CKD have shown clear efficacy at a population level. Yet, individual patients respond differently with many patients showing suboptimal efficacy. This indicates that a ‘one size fits all’ approach is no longer sustainable. Currently there are no validated pharmacodynamic biomarkers in CKD that aid in guiding optimal therapy for individual patients. Furthermore, there remains a large gap between biomarker research and actual implementation of biomarker based care in daily clinical practice. Thus, there is an urgent need to validate and translate biomarkers as tools for daily clinical practice. PRIME-CKD has a unique advantage to address this challenge as it builds on recently discovered pharmacodynamic biomarkers for CKD treatment, and has access to a vast amount of clinical data, bio-samples. PRIME CKD will: 1) Provide a breakthrough in the pharmacotherapy of CKD with the validation and implementation of pharmacodynamic biomarkers which will advance personalized medicine. 2) Scientifically validate innovative clinical trial elements, pipelines and qualification procedures that can be used by researchers, diagnostics industries and regulatory authorities. 3) Establish a Stakeholder Network to truly engage patients, clinicians and other stakeholders in implementation of personalized medicines 4) Develop a roadmap for biomarker use in daily clinical practice for the optimal treatment of CKD. These results will enable clinicians to match patients with CKD with the most effective available drug within the shortest possible timeframe leading to less disease burden and progression of disease, enhanced quality of life and increased cost-efficiency. PRIME-CKD results will thus unlock the potential of biomarkers in healthcare and close the gap between biomarker research and clinical use in daily practice.

Keywords: chronic kidney disease,personalized medicine,pharmacodynamic biomarkers,clinical implementation,
Sonio: Deep-Learning for Detection and Diagnostic of Prenatal Malformations (d3pm)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: France
Call: EIC Accelerator Open (HORIZON-EIC-2022-ACCELERATOR-01, 2022)
Start date: 2023-01-01
End date: 2024-12-31
Duration (months): 24.0
Total project cost (EUR): 5717542.5
EU funding (EUR): 2500000.0
Participants: 1
Project status: CLOSED

1 child out of 33 is born with a congenital malformation in developed countries, leading to mortality & disability which impact the children, the families & healthcare system. Fetal ultrasound is the standard non invasive examination to screen for malformations, but 50% of malformations are not detected at routine exams as fetal ultrasound is very complex, time-consuming & highly operator-dependent. One needs to acquire the right images, interpret them & combine them with blood or/and genetic tests to get the right diagnosis. We created Sonio, an AI one-stop modular software platform to guide OBGYNS & sonographers during fetal ultrasound. The core is the Clinical Brain, a unique mix between fetal medicine & AI, aware of 1.6k anomalies & 450 syndromes. It can prioritize anomalies to identify the most probable diagnoses based on medical history & observed phenotype. With EIC support, we will fully build image recognition & genomics into our platform to revolutionize prenatal diagnosis.

Keywords: fetal ultrasound,congenital malformation,prenatal diagnosis,artificial intelligence,medical imaging,deep learning,advanced computing
Investigating Quantum Stereodynamics in COld REactive Scattering (IQ-SCORES)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Fundamental Constituents of Matter
Panel description: Particle, nuclear, plasma, atomic, molecular, gas, and optical physics
Countries involved: Netherlands
Call: ERC STARTING GRANTS (ERC-2024-STG, 2024)
Start date: 2025-01-01
End date: 2029-12-31
Duration (months): 60.0
Total project cost (EUR): 2147846.0
EU funding (EUR): 2147846.0
Participants: 1
Project status: SIGNED

It is a long-held dream of physical chemists to explore and ultimately control interactions between individual molecules and atoms at the full quantum level. Crossed-molecular-beam methods combined with recent technology allow for highly-detailed experimental studies of molecular collisions. Yet, achieving fully-controlled reactive collision experiments with predetermined outcomes still remains an immense challenge, requiring control and detection of all relevant reactant and product parameters. Our world-unique crossed-beam setup combining Zeeman deceleration and velocity map imaging would enable us to finally tackle this challenge, when combined with recent cutting-edge technologies. This setup has been used successfully to perform high-resolution inelastic collision studies, and we recently started investigating reactive scattering. Here, I propose to perform the first fully-controlled reaction experiment with predetermined outcomes. To this end, I will upgrade our setup to reach collision energies as low as 6 mK, implement laser alignment for manipulating reactant orientations, and employ 3D imaging for detecting product orientations. To achieve this aim, we will first explore resonances and nonstatistical effects in the prototypical S + H2 → SH + H insertion reaction to demonstrate our ability to reach low energies. Simultaneously, we will laser align H2 molecules and employ 3D imaging in a separate setup to decipher molecular orientation (stereodynamical) effects in collisions involving H2. Eventually, all techniques will be merged for a fully-controlled S + H2 reaction experiment, enabling us to dictate the reaction outcome. IQ-SCORES promises profound insight into the reaction (stereo)dynamics at the full quantum level and the long-desired power to dictate reaction outcomes with exceptional precision, thus providing an ultrasensitive test for theory. This pioneering and groundbreaking research will thereby truly revolutionize molecular reaction dynamics.

Keywords: molecular collisions,crossed molecular beams,reactive scattering,inelastic scattering,zeeman deceleration,velocity map imaging,stereodynamics
Advance co-packaged optics enabling high-efficiency cloud computing (ADOPTION)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Digital
Destination: Digital & Emerging Technologies for Competitiveness and Fit for the Green Deal
Action type: Innovation actions
Partnership: Photonics (co-programmed)
Countries involved: Ireland,Czechia,Germany,Netherlands,United Kingdom,Belgium
Call: Advanced optical communication components (Photonics Partnership) (IA) (HORIZON-CL4-2021-DIGITAL-EMERGING-01, 2021)
Start date: 2023-01-01
End date: 2026-06-30
Duration (months): 42.0
Total project cost (EUR): 6364026.25
EU funding (EUR): 5551282.5
Participants: 10
Project status: SIGNED

ADOPTION works toward the goal of proving a low power and low cost solution for intra-data centre networks employing co-packaging of the optical (CPO) transceivers with the packed switch chip. Hyperscale data centres are a fundamental and inextricable part of our digital society. However, data centre power consumption represents a huge global problem accounting for 1% of the global power consumption. Scaling the capacity of the current architectures for intra-data centre networks is also becoming more and more challenging due to the increasing power consumption of the electrical interconnects between electrical packet switches and pluggable optical transceivers. ADOPTION aims at addressing switch capacities scaling beyond 204.8Tb/s with port speeds of 6.4Tb/s by reducing the electrical interconnect lengths using silicon photonics CPO transceiver engines with high power efficiency targeting around 3pJ/bit. ADOPTION will also develop innovative packaging solutions using a two-part assembly separating the electrical and optical layers to simplify processes and increase yield. An advanced active optical alignment for fibre arrays will also be integrated in the assembly process with the aim of reducing assembly time and improving coupling efficiency. With these solutions ADOPTION is targeting the challenging goal of reducing the cost of the optical interfaces to below 50 cents per Gb/s. ADOPTION will also demonstrate disruptive new network architectures for hyper-scale data centres and AI computing clusters utilising optical switching and routing to increase efficiency and reduce latency. ADOPTION is aiming to create a new ecosystem of research and innovation, building on the complementary expertise of 3 SMEs, 3 large companies and 4 research institutions in the consortium, and to redefine the digital supply chain for CPO transceivers, fostering European competitiveness in this new value chain. To fulfil this vision, the consortium is asking for 5.8 M€.

Keywords: ai,silicon photonics,low power computing
Open Modelling Toolbox for development of long-term pathways for the energy system in Africa (OpenMod4Africa)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Energy
Destination: Sustainable, secure and competitive energy supply
Action type: Research and Innovation actions
Countries involved: Norway,France,Italy,Ethiopia,Kenya,Uganda,Germany,Spain,Austria,Switzerland,Benin,Senegal,Tunisia
Call: AU-EU Energy System Modelling (HORIZON-CL5-2022-D3-02, 2022)
Start date: 2023-07-01
End date: 2026-06-30
Duration (months): 36.0
Total project cost (EUR): 2700363.75
EU funding (EUR): 2700363.75
Participants: 18
Project status: SIGNED

OpenMod4Africa aims to develop an open Toolbox populated with state-of-the-art models for analysing long-term pathways to sustainable, secure and competitive energy systems in Africa. The Toolbox will build on EU projects like Open ENTRANCE, Plan4RES and FocusAfrica, and will adapt and further develop open models in accordance with the African context and needs. The models are scalable, and can be applied to cities, industries and countries. Furthermore, a main objective for OpenMod4Africa is capacity building among energy models in academia. Five African universities will be actively involved in adapting models and conducting three regional case studies. The additional capacity and the open Toolbox will enable the universities to train new generations of energy modelling experts for the energy industries in Africa. Three decision-makers will also be engaged, together with a network of energy industries and universities in 25 African countries. These players will be invited to use the Toolbox, and to be involved in training activities. They will also be invited to a permanent network of expertise, which will be developed for further capacity building and collaboration beyond the project. Three case studies will develop energy pathways for rural areas, cities, countries and large regions of countries in Western and Eastern Africa and in Tunisia. The replication strategies will pave the way for further analyses beyond the project. Finally, OpenMod4Africa aims to collaborate with other ongoing initiatives to maximize the impacts of the project and create synergies. The consortium consists of 16 partners and 2 associated partners. Nine partners are African. Important long-term impacts from the three-year project include enabling academia and decision-makers in Africa to conduct their own analyses for the optimal development of their energy system, supplying energy to a much larger share of the population, and establishing a system based upon the abundant share of renewables on the continent.

Keywords: open energy system models,capacity building,stakeholder engagement,permanent network of stakeholders
A novel immuno-oncolytic virus-based dendritic cell therapeutic cancer vaccine (DCanVAX)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Germany
Call: ERC PROOF OF CONCEPT GRANTS (ERC-2023-POC, 2023)
Start date: 2024-02-01
End date: 2025-07-31
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Following decades of development, therapeutic cancer vaccines are beginning to gain momentum in demonstrating therapeutic effects, and they represent a particularly promising approach. The aim of therapeutic cancer vaccines is to stimulate immunity against tumor antigens, usually through the use of whole cells, peptides, or nucleic acids (i.e. mRNAs). Dendritic cell- (DC) based vaccines represent particularly interesting candidates for therapeutic cancer vaccine products due to their ability to cross-present antigens to T cells, thereby driving adaptive immune responses through induction of antigen-specific cytotoxic T lymphocytes. Despite the potential of DC-based cancer vaccines, several major limitations have hindered their success in clinical studies. These limitations include insufficient ex vivo maturation of DCs and challenges in selecting optimal tumor antigens to target. The aim of DCanVAX is to develop a novel oncolytic virus-based dendritic cell vaccine approach for systemic therapy of solid cancers. We propose that the use of a highly immuno-oncolytic virus as a mechanism to lyse tumor cells ex-vivo, will lead to the release of the entire tumor antigen library, as well as a cocktail of danger signals in response to the virus infection. By applying this highly immunogenic lysate to autologous DCs, an optimized and personalized DC vaccine can be generated. This method overcomes the major challenges that have been encountered by DC vaccine approaches in the clinic, by providing a potent mechanism of DC maturation and activation, while simultaneously exposing the DCs to the complete repertoire of tumor antigens that are specific to the patient, leading to potent and broad tumor-specific immune responses against the cancer. This approach can be developed for multiple solid cancer indications and combined with other immunotherapy approaches for potentially synergistic therapeutic effects.
Microglia As conTroller of braIn metaboLism During Aging (MATILDA)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology  of ageing , pathophysiology, inter - organ and tissue communication, endocrinology, nutrition,  metabolism, interaction with the microbiome, non -communicable diseases including cancer (and except disorders of the nervous system  and immunity -related diseases)
Countries involved: Italy
Call: ERC ADVANCED GRANTS (ERC-2021-ADG, 2021)
Start date: 2023-01-01
End date: 2028-12-31
Duration (months): 72.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Microglia represent the main brain residential immune cells. In the last years evidence emerged that, besides representing the first line of defense against pathogenic insults, microglia are also centrally involved in physiological functions essential for correct CNS development and function. Microglia, in a spatially and temporally controlled manner, influence neuronal apoptosis, neurogenesis and myelin formation and manage synapse homeostasis, including removing supernumerary synapses during development. These widely heterogeneous roles are supported by distinct subtypes -or states- of microglia, present in different regions of the brain and at different times during CNS development. In the last years, Triggering Receptor Expressed on Myeloid cells 2 (Trem2) emerged as a key gene which controls the microglial metabolic state, in addition to directing synapse elimination and shaping the functional brain connectivity. In the present project, I propose that microglia, via Trem2, direct the genetic signature of specific subgroups of brain cells, shifting them toward specific metabolic and developmental patterns. I hypothesize that this mechanism is key for the control of metabolism in the hypothalamus, where the neuronal contingents orchestrating systemic energy homeostasis reside. By using a combination of transcriptomics, multiplex protein expression analysis and cell-based imaging methods, I will determine which subsets of microglia cooperate within hypothalamic centers and will define the underlying mechanisms. I will also assess whether defects in this orchestrated crosstalk affect the central regulation of energy and glucose homeostasis during aging. Data from this study will provide comprehensive knowledge of microglia functions in shaping hypothalamic complexity and endocrine output. Also, they will offer a targeting potential for new therapeutic strategies that could reverse immunometabolic dysfunction by modulation of hypothalamic microglial function.

Keywords: microglia,hypothalamus,trem2,hypothalamic neurons,synapses
Local and systemic mechanisms for metabolic inflammation chronicity (LOSYSINCHRON)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology  of ageing , pathophysiology, inter - organ and tissue communication, endocrinology, nutrition,  metabolism, interaction with the microbiome, non -communicable diseases including cancer (and except disorders of the nervous system  and immunity -related diseases)
Countries involved: Germany
Call: ERC ADVANCED GRANTS (ERC-2021-ADG, 2021)
Start date: 2023-03-01
End date: 2028-02-29
Duration (months): 60.0
Total project cost (EUR): 2493275.0
EU funding (EUR): 2493275.0
Participants: 1
Project status: SIGNED

Chronic inflammation underlies several diseases and is a common basis of multiple comorbidities. In obesity, chronic inflammation of the adipose tissue (AT) and liver contributes to the metabolic syndrome and related metabolic-inflammatory pathologies. Here, we propose a thorough and innovative approach to revolutionize understanding of metabolic inflammation chronicity. We will address both local (at the respective tissue level) and systemic mechanisms, involving the novel principle of trained innate immunity (TII) and inflammatory adaptation of the bone marrow (BM). (i) Local: In chronic metabolic inflammation, there is an imbalance between chronic accumulation/activation of inflammatory cells and resolution of inflammation (RoI) in favor of the former. Based on our recent findings regarding integrin-dependent chronic macrophage retention in the obese AT and that Developmental endothelial locus-1 promotes RoI, we will here identify novel pathways towards counter-acting chronicity of metabolic inflammation and facilitating its resolution and test their therapeutic efficacy. (ii) Systemic: Systemic metabolic/inflammatory feedback to the BM may trigger long-term adaptations of hematopoietic progenitors, fueling a feed-forward loop of perpetual inflammation. Following our discovery that TII is initiated in the BM, we will pursue the hypothesis that maladaptive training of BM progenitors in obesity facilitates metabolic inflammation chronicity, via generation of myeloid cells with higher potential for tissue accumulation and inflammatory activation, and promotes development of obesity-related inflammatory comorbidities. Despite apparent links, local and systemic mechanisms are mostly studied independently of each other rather than through an integrative approach, which will be followed here for the first time. Our proposal will lead to breakthrough concepts in metabolic inflammation chronicity and to novel therapeutic strategies for metabolic-inflammatory pathologies.

Keywords: inflammation,resolution of inflammation,integrins,leukocyte adhesion,trained immunity,bone marrow,hematopoietic progenitors,adipose tissue inflammation,metabolism
Integrated COnversion of NItrate and Carbonate streams (ICONIC)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Challenges
Action type: EIC actions
Countries involved: Spain,Ireland,Netherlands,Germany
Call: EIC Pathfinder Challenge: Carbon dioxide and Nitrogen management and valorisation (HORIZON-EIC-2022-PATHFINDERCHALLENGES-01, 2022)
Start date: 2023-11-01
End date: 2026-10-31
Duration (months): 36.0
Total project cost (EUR): 3964666.25
EU funding (EUR): 3964666.25
Participants: 7
Project status: SIGNED

ICONIC (Integrated COnversion of Nitrate and Carbonate streams) pursues the development of a new technology to remediate water ecosystems that have been polluted due to intense agriculture, farming, and CO2 emissions, using electrolysis, to generate globally used chemicals. In particular, ICONIC seeks to convert damaging species responsible of eutrophication and ocean acidification (namely nitrates and carbonates from seawater) into urea, the most important globally produced C-N chemical. Powered by renewables, this offers a path to closing the carbon and nitrogen cycles. ICONIC proposes an integrated electrochemical approach demonstrating, for the first time, the co-electrolysis of carbonates and nitrates into urea selectively, and industrial relevant currents, from seawater using scalable prototypes. Our innovation stems on the accelerated discovery of new catalysts that, based on non-critical raw materials, activate and couple C and N species; their bottom-up synthesis and assembly into mesostructured electrodes to program reaction environments at high current densities; and their implementation into membrane electrode assemblies, all informed by operando characterizations that inform predictive models to guide in the rational design of the catalyst and system. ICONIC leverages interdisciplinary expertise in the areas of chemistry, electrochemistry, materials science, spectroscopies, and engineering, spanning all scales from catalyst design to system-level implementation. ICONIC’s findings would also have positive impact on water-based electrolysis with great decarbonization potential, contributing to their potential operation using abundant seawater.

Keywords: urea electrosynthesis co2 electroreduction nitrogen electroreduction operando spectroscopies accelerated materials discovery